Cell/Gene Tx channel feed

Blue­bird en­dors­es plan for in­stall­ment-based pay­ments for cost­ly gene ther­a­py

7 years ago
Pharma

Take­da builds ar­se­nal for im­muno-on­col­o­gy re­search, cre­ates cell ther­a­py group

7 years ago
R&D
Pharma

No­var­tis' SMA gene-ther­a­py, if priced at $2M, could be more cost-ef­fec­tive than Bio­gen's Spin­raza — ICER

7 years ago
Pharma

No­var­tis gains pri­or­i­ty re­view for SMA gene ther­a­py as in­vestors grap­ple with stick­er shock

7 years ago
Pharma

While Jiankui He gets all the at­ten­tion, don’t over­look the gi­ant step that Ed­i­tas is tak­ing to­day on the CRISPR front

7 years ago
Bioregnum
Opinion

Bol­stered by promis­ing PhI­Ib snap­shot, uniQure plays catch-up with Spark in the race to a he­mo­phil­ia B gene ther­a­py

7 years ago
R&D

The sand­box: Park­er In­sti­tute throws its re­search mus­cle be­hind gene ther­a­py tech for de­stroy­ing can­cer cells

7 years ago
R&D

FDA press­es its cam­paign against rogue re­gen­er­a­tive med play­ers, cites Stem­Genex for il­le­gal sales

7 years ago
Pharma

Sarep­ta shares sink on the back of a mon­ster $500M raise

7 years ago

Gene ther­a­py de­vel­op­er Or­chard prices IPO at $14 to raise $200M

7 years ago
Financing

Spark's CSO is wrap­ping up an­i­mal stud­ies on a gene ther­a­py for Pompe dis­ease as new work in the field sees ex­plo­sive growth

7 years ago
Discovery

Avro­bio shares blast­ed af­ter tri­al up­date sours out­look on gene ther­a­py for Fab­ry dis­ease

7 years ago

Loy­ola is work­ing on a new and im­proved CAR-T prod­uct, look­ing to over­come high-fre­quen­cy side ef­fects

7 years ago
Startups
R&D

No­var­tis drums up EU launch plans as CHMP gives thumbs up to Spark's gene ther­a­py Lux­tur­na

7 years ago

Am­i­cus CEO Crow­ley bags a gene ther­a­py com­pa­ny, a new pipeline — and a great pho­to op — for $100M in cash

7 years ago
Pharma

An­a­lyst of­fers Am­gen a boost for its ri­val an­ti-BC­MA BiTE, blem­ish­ing GSK as well as CAR-T ri­vals Cel­gene and blue­bird

7 years ago

A knock­down-and-re­place gene ther­a­py from Penn re­searchers shows promise in rare eye dis­ease

7 years ago

FDA, NIH look to stream­line over­sight of gene ther­a­pies

7 years ago
Pharma

Mus­tang Bio ven­tures in­to gene ther­a­py, li­cens­ing 'bub­ble boy dis­ease' treat­ment from St. Jude

7 years ago
R&D
Pharma

Fresh from haul­ing in GSK’s bud­get-priced gene ther­a­py group, Or­chard har­vests $150M mega-round. Is it time to IPO?

7 years ago
Financing

Astel­las grabs a biotech tod­dler in $109M buy­out deal for a glau­co­ma gene ther­a­py pro­gram

7 years ago
Deals

FDA lays down the law on gene ther­a­py, of­fer­ing guid­ances on both dis­eases and pro­ce­dures

7 years ago
Pharma

Park­er In­sti­tute sci­en­tists her­ald a cell ther­a­py break­through in the lab, us­ing next-gen CRISPR tech to en­gi­neer T cells

7 years ago

Penn team-biotech col­lab­o­ra­tion high­lights promise of gene edit­ing in tar­get­ing PC­SK9, liv­er dis­eases

7 years ago
Discovery
First page Previous page 53545556575859 Next page Last page
A service from the Financial Times